• Greenlight Biosciences

  Participated · Series D · Jun 2020

  GreenLight Biosciences develops low-cost, scalable RNA products using a patented, cell-free bioprocessing platform to enable commercial RNA applications in agriculture and life sciences. The company aims to commercialize a pipeline of RNA-based agricultural biocontrols and expand into RNA-based therapeutics and vaccines. Its platform dramatically lowers RNA production costs, enabling products that previously were not commercially viable. GreenLight expects its first biopesticide to launch in 2022 and is pursuing a commercially available mRNA-based COVID-19 vaccine. The company highlights applications across plant, human, and animal health and emphasizes environmentally friendly crop protection that avoids residues and spares beneficial insects. GreenLight Biosciences is a Boston-based biotech that specializes in producing messenger RNA (mRNA) for vaccines. The company is focused on scaling mRNA manufacturing capacity to support the creation of "billions of doses" of potential COVID-19 vaccines for trials and potential deployment. GreenLight is also developing several versions of its own mRNA-based vaccine candidates targeting SARS-CoV-2. Some of the new funding will be used both to expand production capacity and to advance those vaccine candidates. The article characterizes mRNA vaccines as a relatively novel approach that contain no actual virus and can shorten pre-clinical development timelines. GreenLight raised special-purpose funding to support these manufacturing and development efforts. GreenLight Biosciences develops RNA products for plant and life science applications, focusing on agricultural bio-control products and human and animal vaccines and therapeutics. The company collaborates with industry leaders and academic institutions to advance vaccine development, pandemic preparation, crop management, and plant protection. Led by Co-Founder and CEO Andrey Zarur, GreenLight is expanding its discovery and development capabilities across multiple segments. The firm operates Plant Sciences R&D in RTP, NC and St. Louis, MO. Management says the work spans a portfolio of bio-performance candidates for plant and life sciences. The company intends to accelerate development through existing partnerships and the newly raised capital. GreenLight Biosciences develops RNA-based products for agriculture using its Cell-Free Bioprocessing® platform. The company focuses on dsRNA molecules designed to directly target insect and viral pests in high-value crops while sparing beneficial organisms and minimizing environmental impact. It is also developing additional RNA offerings in public health, vaccine development and human therapeutics. Led by Co-Founder and CEO Andrey J. Zarur, Ph.D., GreenLight plans to use new capital to accelerate development and field testing of several dsRNA molecules and to build up its team. The company recently completed a Series D financing and is based in Medford, Mass. GreenLight Biosciences is a Medford, Mass.-based developer of a cell-free approach to microbial chemical production. The company builds a bio-based manufacturing platform to produce chemicals from renewable, non-petroleum resources. Its core technology focuses on cell-free production methods intended to enable cleaner, scalable chemical manufacturing. GreenLight is led by Andrey Zarur, Ph.D., Co-Founder, CEO and Chairman. Financially, the company completed a Series C financing in July 2015; the amount was undisclosed. The round included participation from both new and existing investors and was led by MLS Capital Fund II.

• Inscripta

  Participated · Series C · Apr 2019

  Inscripta develops the Onyx digital genome engineering platform, a benchtop system combining an instrument, consumables, software and assays to enable scalable, automated CRISPR-based workflows and massively parallel, trackable single-cell edits. The company announced the first commercial shipment of Onyx to customers including the GeneMill at the University of Liverpool and cites customers such as Sestina Bio. Onyx is designed to accelerate the four steps of synthetic biology—design, generate, test, and learn—via InscriptaDesigner, Onyx Genome Engineering Kits, genotyping assays, and InscriptaResolver software. Inscripta highlights an IP portfolio of nearly 100 issued U.S. patents and frames the platform as enabling faster genome engineering cycles with fewer resources. The company is headquartered in Boulder, Colorado, with offices in San Diego and Pleasanton, California, and Copenhagen, Denmark. Inscripta closed a $150 million Series E financing to support commercial scaling and product deployment. Inscripta develops the Onyx Digital Genome Engineering platform, a fully automated benchtop instrument for genome-scale engineering. The platform comprises an instrument, consumables, software, and assays and enables creation of libraries of millions of precisely engineered single cells in one experiment through a fully automated workflow. Inscripta says the platform overcomes limitations of existing CRISPR-based gene editing and enables massively parallel, trackable editing of single cells at unprecedented scale. The company plans to use new funding to accelerate applications expansion and commercialization of Onyx to meet anticipated high demand. Financially, Inscripta raised $125 million in a Series D, bringing total capital raised to $259.5 million. The company is headquartered in Boulder, Colo., with offices in Pleasanton, Calif., and San Diego, and is backed by investors including Venrock, Foresite, Paladin Capital Group, Mérieux Développement, NanoDimension, MLS Capital, JS Capital Management, and Oak HC/FT. Inscripta develops a full suite of gene editing tools—software, instruments, reagents—and a family of CRISPR enzymes (MADzymes) intended to increase the speed and efficiency of multiplexed, single-cell gene editing. Its product portfolio includes the proprietary MAD7 enzyme, which the company has offered to commercial and academic researchers with no up-front licensing fees or reach-through royalties. Inscripta says these tools remove barriers to single-cell engineering and aim to enable advances to "feed, fuel, and heal humanity." The company expanded its Series C financing to support commercialization and market introduction of its solutions. Inscripta increased its Series C by $20M to a total of $105.5M, adding to an $85.5M financing announced in 2018. The company is led by CEO Kevin Ness and board chairman John Stuelpnagel and is headquartered in Boulder, Colo., with offices in Pleasanton, Calif., and San Diego. Inscripta develops tools for forward cell engineering, including a family of CRISPR enzymes called MADzymes, custom nucleases for researchers and commercial partners, and integrated instruments, reagents and software. Its products are designed to increase the speed and efficiency of multiplexed, precision gene editing. The company is led by CEO Kevin Ness and is based in Boulder, CO and Pleasanton, CA. Inscripta completed a $55.5M Series C financing and plans to use the proceeds to expand research capabilities and strengthen its internal team of research experts. No operating metrics were disclosed in the article.

• LanzaTech

  Participated · Series D · Mar 2014

  On January 27, 2026, LanzaTech Global Inc. disclosed that it has successfully closed a private placement financing, according to Ethanol Producer Magazine. The article does not provide details on the company’s core technology, revenue, user base, or broader business model, focusing solely on the financing event. No information on future projects or strategic initiatives was shared in this piece. Likewise, the report offers no operating metrics such as annual revenue, production capacity, or customer figures. The announcement was simply positioned as a milestone that supplies additional capital for LanzaTech’s next phase of activities. The company released no specifics regarding how the proceeds will be allocated.

• Glori Energy

  Participated · Series C · Jan 2012

  Glori Energy develops and deploys the AERO™ (Activated Environment for Recovery of Oil) System to increase oil recovery from existing wells by optimizing non‑potable water to activate indigenous reservoir microbes. The company sells its AERO service and plans to expand that service business while acquiring shut‑in or low‑producing mature fields for redevelopment using its technology. Glori intends to deploy the system in acquired fields to demonstrate proven results that will drive product revenue and customer adoption. The AERO System aims to recover trapped oil with minimal new footprint or capital investment. The company emphasizes sustainable, efficient recovery leveraging existing wells and water sources. The article lists Houston as the company’s location in the announcement.

• Chromatin

  Participated · Series D · Oct 2011

  Chromatin is a Chicago-based company that produces sorghum seed for food and as feedstock for animals and biofuels. Sorghum is native to the Old World, related to sugarcane, can be grown on 80% of the world’s arable land, and is known for rapid maturation, weather tolerance, and high yields. The company will use the Series F proceeds to set up manufacturing overseas and create an operating footprint in some regions for logistics reasons as it expands into international markets. Chromatin announced a $12 million Series F from Illinois Ventures and Wood Creek Capital Management. This follows a $36 million Series E in January 2014 and a $12.5 million debt financing in July, bringing total capital raised to $72.1 million. Previous investors include BP, GE Capital, the Malaysian Life Sciences Capital Fund, Unilever, and Foragen Technology Ventures. Chromatin now employs over 150 people. Chromatin develops and sells sorghum seed varieties used in food, feed and renewable fuel and power applications. Its sorghum products are described as high‑yielding, rapidly maturing and tolerant of heat, cold and drought. Rising demand for water‑efficient crops has driven steady increases in Chromatin’s domestic and global sorghum market share over the past four years. The company says its products provide high‑performance feedstocks for multiple end markets. To support its rapidly expanding sorghum seed business, Chromatin secured a three‑year, $12.5 million credit facility that will be available for working capital and general corporate purposes. The company has also raised over $70 million in equity financing and reports predictable recurring revenue and a strong balance sheet. Chromatin develops and sells proprietary sorghum seed varieties for traditional agriculture and emerging bio-based industries such as liquid transportation fuels, chemicals, materials and biopower. Its products are optimized for rapid maturation, tolerance to heat, cold and drought, high yields, and nutrient efficiency. Chromatin's seed is sold in the U.S. and in more than 20 countries and is planted on over 4 million acres. Significant market demand for its proprietary sorghum products is driving the company's rapid growth. The company says it will use the newly raised capital to support expansion and accelerate product development and differentiation for sales in both U.S. and international markets. With the Series E first closing, Chromatin has now raised over $70 million of equity in aggregate. Chromatin is a Chicago-based developer of energy-crop feedstock solutions that has marketed gene-stacking technologies enabling the delivery of multiple genetic traits into plants. Founded in 2000 and venture-backed, the company is developing and commercializing a portfolio of proprietary sorghum feedstocks targeted at the renewable energy sector. Chromatin received a $5.7M award under the PETRO program of the U.S. Department of Energy’s ARPA-E. The award will fund a three-year program to develop new varieties of sweet sorghum for use as an energy-rich, low-cost feedstock for transportation fuels. The company’s core work combines its gene-stacking platform with crop development to produce tailored energy-crop feedstocks. The article does not disclose revenue, users, or other operating metrics. Chromatin supplies renewable biomass feedstocks for power, fuel and chemical producers of renewable energy. It develops high-value sorghum seeds using proprietary crop-breeding technology and biotechnology programs and licenses gene-stacking technologies to other agriculture companies. Chromatin applies its technology platforms to its subsidiary, Sorghum Partners LLC, which markets and supplies hybrid sorghum seeds to growers in the U.S. and more than 20 other countries. The company completed a $10m first closing of its Series D financing and intends to use the funds to advance supply chains of energy crop feedstocks. Backers in the round include BP Ventures and Unilever Technology Ventures alongside existing investors Quantitative Investment Holdings, the Malaysian Life Sciences Capital Fund and Illinois Ventures. Led by CEO Daphne Preuss, Chromatin combines seed development, licensing and feedstock supply to serve renewable energy markets.

No current team members are available.